AbbVie doubles down on siRNA with $335M upfront bet on ADARx
Article Title: AbbVie doubles down on siRNA with $335M upfront bet on ADARx Publication Date: May 14, 2025 Building upon its $1.4 billion acquisition of Alnylam Therapeutics in the previous year, AbbVie has announced a substantial $335 million upfront investment…